The market for 5G applications is expected to grow significantly in the next decade. Major 5G players such as Qualcomm have traditionally used ASICs because of the economies of scale. However, there are a growing number of mid-sized companies that are developing FPGA solutions for 5G modems. The team has implemented FPGA blocks such as FFTs and FIR filters with less area, lower power, and shorter processing times. They also completed more than 130 Voice of Customer interviews with managers and engineers working in this area. The discussions and the feedback has validated the value of this technology in their area. During the discussions, the team identified companies as potential partners.
Nearly 1.6 million Americans have Type 1 Diabetes (T1D), an autoimmune class of diabetes. Additionally, ~3.2 million Americans develop latent autoimmune diabetes of adults (LADA). For T1D or LADA patients, immunotherapy promises a path to reprogram the immune system such that it no longer attacks and destroys insulin-producing beta cells in the pancreas. SermAb Biologics is developing a monoclonal antibody therapy against serpinB13. SermAb Biologics focuses on the discovery that tissue regeneration is stimulated by blocking serpinB13 and restoring the activity of its protease target. The second advantage is that our antibody to serpinB13 suppresses inflammation, increases beta-cell proliferation, and delays the onset of diabetes. Thus, by using a single reagent that regulates the balance between serpin inhibitor and protease, we can simultaneously suppress the inflammatory response while promoting regenerative changes in the pancreas and other tissues expressing serpinB13.
One of the most worrisome complications of the current global pandemic of COVID-19 is acute respiratory distress syndrome (ARDS), which is characterized by excess inflammation and fluid in the lung and has high mortality despite years of study. Research has indicated that more than 40% of the individuals hospitalized with severe COVID-19 develop ARDS and over half of those cases are fatal. A team of researchers at the University of Minnesota with decades of research knowledge surrounding lung diseases have developed a novel and promising treatment approach for ARDS utilizing Liothyronine (T3), a synthetic form of thyroid hormone that already has FDA approval. Application of T3 to injured lungs has been shown to speed fluid clearance in animal models and clinical trials are already underway to validate translation to humans suffering with ARDS.